Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial

@article{GonzalezRivera2016FrequencyOG,
  title={Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial},
  author={Milagros Gonzalez-Rivera and Miriam Lobo and Sara L{\'o}pez-Tarruella and Yolanda Jerez and Mar{\'i}a del Monte-Mill{\'a}n and Tatiana Massarrah and Roc{\'i}o Ramos-Medina and Inmaculada Oca{\~n}a and Antoni C Picornell and Sonia Santill{\'a}n Garz{\'o}n and Luc{\'i}a P{\'e}rez-Carbornero and Jos{\'e} Angel Garc{\'i}a-Saenz and Henry G{\'o}mez and Fernando Moreno and Iv{\'a}n M{\'a}rquez-Rodas and Hugo Fuentes and Miguel Mart{\'i}n},
  journal={Breast Cancer Research and Treatment},
  year={2016},
  volume={156},
  pages={507-515}
}
We describe the status and frequency of germline DNA genetic findings in an unselected prospective cohort of triple negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. Study population includes 124 consecutive patients with stage II-III TNBC from a trial exploring the antitumor activity of neoadjuvant carboplatin/docetaxel chemotherapy enrolled between 2012 and March 2015, to determine the frequency of germline DNA genetic mutations. 17.1 % of the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 46 references

Similar Papers

Loading similar papers…